论文部分内容阅读
目的观察不同胰岛素给药途径对新诊断T2DM的疗效。方法将84例新诊断T2DM患者随机分为胰岛素持续皮下注射治疗(CSII)组和胰岛素多次皮下注射(MSII)组,每组各42例。观察治疗及出院1年后相关指标。结果两组治疗后血糖均下降。与MSII组比较,CSII组血糖达标时间短[(11.2±3.4)vs(7.3±2.1)d,P<0.05];胰岛素用量偏少[(0.90±0.21)vs(0.65±0.16)IU/(kg·d),P<0.05]。出院1年后,在未采用药物治疗情况下,血糖控制达标者CSII组多于MSII组(36例vs 16例)。结论胰岛素持续皮下注射治疗新诊断T2DM患者,在住院期间及出院1年后疗效和安全性优于胰岛素多次皮下注射治疗。
Objective To observe the effect of different insulin administration on newly diagnosed T2DM. Methods Eighty-four newly diagnosed T2DM patients were randomly divided into continuous insulin subcutaneous injection (CSII) group and multiple insulin subcutaneous injection (MSII) group, 42 cases in each group. Observe the treatment and discharge after 1 year related indicators. Results After treatment, blood glucose decreased in both groups. Compared with MSII group, the blood glucose level of CSII group was shorter than that of MSII group [(11.2 ± 3.4) vs (7.3 ± 2.1) d, P <0.05], insulin dose was less than [0.90 ± 0.21 vs 0.65 ± 0.16 IU / kg · D), P <0.05]. One year after discharge, more patients in the CSII group did not receive medication than those in the MSII group (36 vs. 16). Conclusions Insulin continuous subcutaneous injection in the treatment of newly diagnosed T2DM patients is superior to multiple subcutaneous injections of insulin in hospitalization and 1 year after discharge.